Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00968968
First received: August 27, 2009
Last updated: August 7, 2016
Last verified: August 2016
  Purpose
This is a randomized, open-label, multi-center Phase III study evaluating the efficacy and safety of lapatinib in combination with trastuzumab versus trastuzumab alone as continued HER2 suppression therapy in women with HER2-positive metastatic breast cancer (MBC). Eligible subjects will have completed 12 to 24 weeks of first- or second-line treatment with trastuzumab plus chemotherapy, experienced either complete disappearance of all metastatic lesions, or persistence of metastatic disease (stable disease) without unequivocal progression or the occurrence of new lesions, and been indicated to continue to receive trastuzumab alone as maintenance therapy. Eligible subjects entering the LPT112515 study on first-line treatment will have no known history of central nervous system (CNS) metastases; subjects entering the study on second-line treatment will have no known history of CNS metastases or have stable (asymptomatic and off steroids ≥3 months) CNS metastases. The primary objective of this study is to compare progression-free survival (PFS) in subjects with HER2-positive MBC randomized to receive treatment with lapatinib plus trastuzumab versus those randomized to receive trastuzumab alone. The secondary objectives include overall survival, clinical benefit response rate (CR, PR or SD ≥24 weeks) and the qualitative and quantitative adverse event profile of the 2 treatment arms. It is estimated that 280 subjects (140 per group) will be required to observe 193 PFS events.

Condition Intervention Phase
Cancer
Drug: Lapatinib
Biological: Trastuzumab
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Progression-free survival [ Time Frame: Time from randomization until disease progression or death ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall survival [ Time Frame: Time from randomization until death ] [ Designated as safety issue: No ]
  • Clinical benefit response rate (CR, PR or SD ≥24 weeks) [ Time Frame: End of Study ] [ Designated as safety issue: No ]
  • Determine the qualitative and quantitative adverse event profile of the 2 treatment arms [ Time Frame: End of Study ] [ Designated as safety issue: No ]

Enrollment: 280
Study Start Date: January 2010
Estimated Study Completion Date: March 2017
Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1: Lapatinib plus Trastuzumab Drug: Lapatinib
Oral Lapatinib 1000 mg once daily. Lapatinib is a small molecule, reversible inhibitor targeting HER2 tyrosine kinase receptor.
Biological: Trastuzumab
IV Trastuzumab 6 mg/kg every three weeks. Trastuzumab is a humanized, monoclonal antibody directed against the extracellular domain of the HER2 tyrosine kinase receptor.
Active Comparator: Arm 2: Trastuzumab Biological: Trastuzumab
IV Trastuzumab 6 mg/kg every three weeks. Trastuzumab is a humanized, monoclonal antibody directed against the extracellular domain of the HER2 tyrosine kinase receptor.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed the informed consent form (ICF)
  • Female, ≥18 years of age
  • Histologically verified breast cancer with distant metastases (metastatic breast cancer)
  • Documentation of HER2 overexpression or gene amplification in the invasive component of either the primary tumor or metastatic disease site defined as:
  • 3+ by IHC and/or
  • HER2/neu gene amplification by fluorescence, chromogenic or silver in situ hybridization [FISH, CISH or SISH; >6 HER2/neu gene copies per nucleus or a FISH, CISH or SISH HER2 gene copies to chromosome 17 signal ratio of ≥2.0]
  • Completed 12 to 24 weeks of first- or second-line treatment with trastuzumab in combination with chemotherapy
  • Either complete disappearance of all lesions, or persistence of metastatic disease (stable disease) without unequivocal progression or the occurrence of new lesions
  • Documentation of lesion response during the course of therapy received prior to randomization (i.e., improvement or no worsening of tumor burden; the absence of new lesions)
  • Measurable disease is not required for study participation
  • No known or suspected (associated neurological signs and symptoms) brain metastases (including leptomeningeal involvement)
  • Stable brain metastasis (defined as asymptomatic and off steroids ≥3 months) are permitted in subjects entering LPT112515 on second-line treatment (completed 12-24 weeks of second-line treatment with trastuzumab plus chemotherapy)
  • Baseline of Left Ventricular Ejection Fraction (LVEF) ≥50% measured by echocardiography (ECHO) or multi-gated acquisition scan (MUGA)
  • Completion of screening assessments (Refer to protocol for further details)
  • Have adequate marrow and organ function as defined in Table 2. Table 2 Laboratory Values SYSTEM LABORATORY VALUES Hematologic ANC ≥1.5 x 109/L Hemoglobin ≥9 g/dL (after transfusion if needed) Platelets ≥100 x 109/L Hepatic Albumin ≥2.5 g/dL Serum bilirubin ≤1.5 x ULN unless due to Gilbert's syndrome AST and ALT ≤3 x ULN Renal Calculated creatinine clearance* ≥ 40 mL/min Serum Creatinine ≤1.5 mg/dL or 132.6μmol/L *Calculated by the Cockcroft-Gault Equation (Refer to protocol for details) Abbreviations: ANC, absolute neutrophil count; ULN, upper limit of normal; AST, aspartate aminotransferase; ALT, alanine aminotransferase

Exclusion Criteria:

  • History of other malignancy. Subjects who have been disease-free for 5 years or subjects with a history of completely resected non-melanoma skin cancer (basal or squamous) are eligible
  • Eastern Cooperative Oncology Group (ECOG) Performance Status >2
  • Concurrent anti-cancer treatment, except anti-hormonal therapy for subjects with hormone receptor positive breast cancer
  • Concurrent treatment with an investigational agent
  • Prior treatment with anti-HER2 therapy, except trastuzumab or lapatinib
  • Concurrent treatment with protocol-defined prohibited medications (refer to protocol for details)
  • Serious cardiac illness or medical condition including but not confined to:
  • Uncontrolled arrhythmias
  • Uncontrolled or symptomatic angina
  • History of congestive heart failure (CHF)
  • Myocardial infarction <6 months from study entry
  • Acute or current active (requiring anti-viral therapy) hepatic or biliary disease (with the exception of subjects with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
  • Concurrent disease or condition that may interfere with study participation, or any serious medical disorder that would interfere with the subject's safety (for example, active or uncontrolled infection or any psychiatric condition prohibiting understanding or rendering of informed consent)
  • Women of childbearing potential, including women whose last menstrual period was <12 months ago (unless surgically sterile) who are unable or unwilling to use adequate contraceptive measures during the study treatment period. Adequate contraception includes intra-uterine device, barrier methods with spermicide, or oral contraceptives (unless clinically contraindicated for the subject population or per local practice, refer to protocol for further details)
  • Pregnant or lactating females
  • Any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.
  • Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to any of the study agents or their excipients that, in the opinion of the Investigator or GSK medical monitor , contra-indicates participation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00968968

  Hide Study Locations
Locations
United States, Arizona
Novartis Investigative Site
Chandler, Arizona, United States, 85224
Novartis Investigative Site
Flagstaff, Arizona, United States, 86001
Novartis Investigative Site
Gilbert, Arizona, United States, 85297
Novartis Investigative Site
Mesa, Arizona, United States, 85202
Novartis Investigative Site
Mesa, Arizona, United States, 85206
Novartis Investigative Site
Sedona, Arizona, United States, 86336
Novartis Investigative Site
Tucson, Arizona, United States, 85724
United States, California
Novartis Investigative Site
Bakersfield, California, United States, 93309
Novartis Investigative Site
Beverly Hills, California, United States, 90211
Novartis Investigative Site
Fullerton, California, United States, 92835
Novartis Investigative Site
La Jolla, California, United States, 92037
Novartis Investigative Site
La Jolla, California, United States, 92093-0987
Novartis Investigative Site
Long Beach, California, United States, 90813
Novartis Investigative Site
Los Angeles, California, United States, 90095- 7187
Novartis Investigative Site
San Diego, California, United States, 92103-8411
Novartis Investigative Site
San Pablo, California, United States, 94806
Novartis Investigative Site
Santa Maria, California, United States, 93454
United States, Florida
Novartis Investigative Site
Hollywood, Florida, United States, 33021
Novartis Investigative Site
Hudson, Florida, United States, 34667
Novartis Investigative Site
New Port Richey, Florida, United States, 34655
United States, Georgia
Novartis Investigative Site
Augusta, Georgia, United States, 30901
Novartis Investigative Site
Augusta, Georgia, United States, 30909
Novartis Investigative Site
Dublin, Georgia, United States, 31021
United States, Illinois
Novartis Investigative Site
Arlington Heights, Illinois, United States, 60005
Novartis Investigative Site
Chicago, Illinois, United States, 60611
Novartis Investigative Site
Evanston, Illinois, United States, 60201
Novartis Investigative Site
Glenview, Illinois, United States, 60025
Novartis Investigative Site
Highland Park, Illinois, United States, 60035
Novartis Investigative Site
Joliet, Illinois, United States, 60435
Novartis Investigative Site
Niles, Illinois, United States, 60714
Novartis Investigative Site
Peoria, Illinois, United States, 61615
Novartis Investigative Site
Peoria, Illinois, United States, 61636
Novartis Investigative Site
Peoria, Illinois, United States, 61637
Novartis Investigative Site
Skokie, Illinois, United States, 60076
Novartis Investigative Site
Winfield, Illinois, United States, 60190
United States, Indiana
Novartis Investigative Site
Goshen, Indiana, United States, 46526
Novartis Investigative Site
Mishawaka, Indiana, United States, 46545
United States, Maryland
Novartis Investigative Site
Columbia, Maryland, United States, 21044
Novartis Investigative Site
Silver Spring, Maryland, United States, 20910
United States, Massachusetts
Novartis Investigative Site
Boston, Massachusetts, United States, 02114
Novartis Investigative Site
Boston, Massachusetts, United States, 02215
United States, Michigan
Novartis Investigative Site
Brownstown, Michigan, United States, 48183
Novartis Investigative Site
Dearborn, Michigan, United States, 48126
Novartis Investigative Site
Detroit, Michigan, United States, 48202
Novartis Investigative Site
West Bloomfield, Michigan, United States, 48322
United States, Minnesota
Novartis Investigative Site
Brunsville, Minnesota, United States, 55337
Novartis Investigative Site
Coon Rapids, Minnesota, United States, 55433
Novartis Investigative Site
Edina, Minnesota, United States, 55435
Novartis Investigative Site
Fridley, Minnesota, United States, 55432
Novartis Investigative Site
Maplewood, Minnesota, United States, 55109
Novartis Investigative Site
Minneapolis, Minnesota, United States, 55404
Novartis Investigative Site
St. Paul, Minnesota, United States, 55102
Novartis Investigative Site
Woodbury, Minnesota, United States, 55125
United States, Missouri
Novartis Investigative Site
Columbia, Missouri, United States, 65201
Novartis Investigative Site
Jefferson City, Missouri, United States, 65109
United States, Montana
Novartis Investigative Site
Billings, Montana, United States, 59102
United States, Nevada
Novartis Investigative Site
Henderon, Nevada, United States, 89052
Novartis Investigative Site
Henderson, Nevada, United States, 89052
Novartis Investigative Site
Henderson, Nevada, United States, 89074
Novartis Investigative Site
Las Vegas, Nevada, United States, 89128
Novartis Investigative Site
Las Vegas, Nevada, United States, 89148
Novartis Investigative Site
Las Vegas, Nevada, United States, 89169
United States, North Carolina
Novartis Investigative Site
Cary, North Carolina, United States, 27518
Novartis Investigative Site
Elizabeth City, North Carolina, United States, 27909
Novartis Investigative Site
Greensboro, North Carolina, United States, 27403
Novartis Investigative Site
Raleigh, North Carolina, United States, 27607
Novartis Investigative Site
Raleigh, North Carolina, United States, 27614
Novartis Investigative Site
Washington, North Carolina, United States, 27889
United States, Pennsylvania
Novartis Investigative Site
Abington, Pennsylvania, United States, 19001
Novartis Investigative Site
Philadelphia, Pennsylvania, United States, 19106
Novartis Investigative Site
Radnor, Pennsylvania, United States, 19087
United States, Texas
Novartis Investigative Site
Abilene, Texas, United States, 79606-5208
Novartis Investigative Site
Beaumont, Texas, United States, 77701
Novartis Investigative Site
Bedford, Texas, United States, 76022
Novartis Investigative Site
Dallas, Texas, United States, 75230
Novartis Investigative Site
El Paso, Texas, United States, 79902
Novartis Investigative Site
El Paso, Texas, United States, 79915
Novartis Investigative Site
Fort Worth, Texas, United States, 76104
Novartis Investigative Site
Fort Worth, Texas, United States, 76132
Novartis Investigative Site
Garland, Texas, United States, 75042
Novartis Investigative Site
Grapevine, Texas, United States, 76051
Novartis Investigative Site
Houston, Texas, United States, 77024
Novartis Investigative Site
Kerrville, Texas, United States, 78028
Novartis Investigative Site
Odessa, Texas, United States, 79761
Novartis Investigative Site
Plano, Texas, United States, 75075
Novartis Investigative Site
Plano, Texas, United States, 75093
Novartis Investigative Site
San Antonio, Texas, United States, 78217
Novartis Investigative Site
San Antonio, Texas, United States, 78258-3912
United States, Utah
Novartis Investigative Site
Bountiful, Utah, United States, 84010
Novartis Investigative Site
Layton, Utah, United States, 84041
Novartis Investigative Site
Murray, Utah, United States, 84157-7000
Novartis Investigative Site
Provo, Utah, United States, 84604
Novartis Investigative Site
Salt Lake City, Utah, United States, 84102
Novartis Investigative Site
Salt Lake City, Utah, United States, 84106
Novartis Investigative Site
Sandy, Utah, United States, 84094
United States, Virginia
Novartis Investigative Site
Arlington, Virginia, United States, 22205
Novartis Investigative Site
Chesapeake, Virginia, United States, 23320
Novartis Investigative Site
Fairfax, Virginia, United States, 22031
Novartis Investigative Site
Gainesville, Virginia, United States, 20155
Novartis Investigative Site
Hampton, Virginia, United States, 23666
Novartis Investigative Site
Leesburg, Virginia, United States, 20176
Novartis Investigative Site
Newport News, Virginia, United States, 23606
Novartis Investigative Site
Norfolk, Virginia, United States, 23502
Novartis Investigative Site
Virginia Beach, Virginia, United States, 23456
Novartis Investigative Site
Williamsburg, Virginia, United States, 23185
Novartis Investigative Site
Woodbridge, Virginia, United States, 22191
United States, Washington
Novartis Investigative Site
Edmunds, Washington, United States, 98026
Novartis Investigative Site
Federal Way, Washington, United States, 98003
Novartis Investigative Site
Gig Harbor, Washington, United States, 98332
Novartis Investigative Site
Lakewood, Washington, United States, 98499
Novartis Investigative Site
Puyallup, Washington, United States, 98372
Novartis Investigative Site
Seattle, Washington, United States, 98104
Novartis Investigative Site
Seattle, Washington, United States, 98133
Novartis Investigative Site
Tacoma, Washington, United States, 98405
Canada, Nova Scotia
Novartis Investigative Site
Halifax, Nova Scotia, Canada, B3H 1V7
Canada, Ontario
Novartis Investigative Site
Brampton, Ontario, Canada, L6R 3J7
Novartis Investigative Site
Oshawa, Ontario, Canada, L1G 2B9
Canada, Quebec
Novartis Investigative Site
Rimouski, Quebec, Canada, G5L 5T1
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00968968     History of Changes
Other Study ID Numbers: 112515 
Study First Received: August 27, 2009
Last Updated: August 7, 2016
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Lapatinib
Trastuzumab
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 27, 2016